INNOVADERM CRO IS NOW INDERO.

Improving Patient Recruitment in Clinical Trials

John Clarke, MSc

John Clarke, MSc

Associate Director, Patient Recruitment

Author picture

In Bioscience Today, John Clarke, Associate Director in Patient Recruitment at Indero, provides an insightful analysis on improving patient recruitment in clinical trials. This article addresses:

  • The challenges faced by pharmaceutical companies in enrolling participants, especially when existing treatments are well established.
  • Clarke discusses the increasing regulatory expectations for diversity in trials and the importance of designing studies that reflect real-world patient populations.
  • He emphasizes the need to understand patient needs and expectations, reduce logistical barriers, and engage patient advocacy groups to make trials more accessible and appealing.

For a comprehensive understanding of these strategies, follow the link to read the full article here:
  Read More

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.